BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
45.34
-0.67 (-1.46%)
At close: Feb 13, 2026

SHA:688166 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
1,1461,2481,1611,0131,050783.71
Other Revenue
34.2734.2718.344.042.251.67
1,1801,2831,1801,0171,052785.38
Revenue Growth (YoY)
-4.95%8.73%15.94%-3.33%34.00%56.09%
Cost of Revenue
575.2560.51542.9390.95470.07363.39
Gross Profit
604.78722.04636.61626.38582.34421.99
Selling, General & Admin
245.21210.87180.46184.98145.5699.04
Research & Development
301.5297.45248.59207.02173.29138.26
Other Operating Expenses
6.411.39-1.595.224.222.4
Operating Expenses
554.31521.27428.37395333.18238.89
Operating Income
50.46200.76208.24231.38249.16183.11
Interest Expense
-61.22-52.44-44.42-23.71-9.7-2.04
Interest & Investment Income
10.1410.9617.996.210.1413.01
Currency Exchange Gain (Loss)
1.921.922.612.994.63-11.02
Other Non Operating Income (Expenses)
3.34-2.14-1.88-2.17-1.77-0.92
EBT Excluding Unusual Items
4.63159.07182.54224.68252.46182.13
Impairment of Goodwill
-4.38-4.38----
Gain (Loss) on Sale of Investments
-18.95-17.33-15.26-3.390.790.04
Gain (Loss) on Sale of Assets
-0.44-0.15-0.25-0.01-0.26-0.27
Asset Writedown
2.48-----
Other Unusual Items
28.219.9921.7420.934.479.42
Pretax Income
11.54157.2188.77242.21257.46191.32
Income Tax Expense
-14.3515.9415.3530.7819.921.96
Earnings From Continuing Operations
25.89141.26173.42211.43237.56169.36
Minority Interest in Earnings
36.1947.929.0428.26.390.52
Net Income
62.08189.17202.47239.62243.95169.88
Net Income to Common
62.08189.17202.47239.62243.95169.88
Net Income Growth
-66.99%-6.57%-15.51%-1.77%43.60%52.93%
Shares Outstanding (Basic)
418420422413407414
Shares Outstanding (Diluted)
418420422413407414
Shares Change (YoY)
-0.21%-0.34%2.10%1.61%-1.87%11.90%
EPS (Basic)
0.150.450.480.580.600.41
EPS (Diluted)
0.150.450.480.580.600.41
EPS Growth
-66.92%-6.25%-17.24%-3.33%46.34%36.67%
Free Cash Flow
-144.61-11.64-209-415.47-733.59-199.84
Free Cash Flow Per Share
-0.35-0.03-0.49-1.01-1.80-0.48
Dividend Per Share
0.0960.0960.0960.1140.1200.084
Dividend Growth
---15.79%-5.00%42.86%2.44%
Gross Margin
51.25%56.30%53.97%61.57%55.33%53.73%
Operating Margin
4.28%15.65%17.66%22.74%23.67%23.31%
Profit Margin
5.26%14.75%17.16%23.55%23.18%21.63%
Free Cash Flow Margin
-12.26%-0.91%-17.72%-40.84%-69.71%-25.45%
EBITDA
168.02296.58275.07271.03283.34213.31
EBITDA Margin
14.24%23.12%23.32%26.64%26.92%27.16%
D&A For EBITDA
117.5695.8266.8339.6534.1830.2
EBIT
50.46200.76208.24231.38249.16183.11
EBIT Margin
4.28%15.65%17.66%22.74%23.67%23.31%
Effective Tax Rate
-10.14%8.13%12.71%7.73%11.48%
Revenue as Reported
1,1801,2831,1801,0171,052785.38
Advertising Expenses
---0.521.011.32
Source: S&P Global Market Intelligence. Standard template. Financial Sources.